17 results on '"Frattarelli N"'
Search Results
2. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
- Author
-
Tiacci, E., primary, De Carolis, L., additional, Simonetti, E., additional, Zaja, F., additional, Capponi, M., additional, Ambrosetti, A., additional, Lucia, E., additional, Antolino, A., additional, Pulsoni, A., additional, Ferrari, S., additional, Zinzani, P., additional, Rigacci, L., additional, Gaidano, G., additional, Della Seta, R., additional, Frattarelli, N., additional, Falcucci, P., additional, Visani, G., additional, Foà, R., additional, and Falini, B., additional
- Published
- 2019
- Full Text
- View/download PDF
3. PEG INTRON IN ESSENTIAL THROMBOCYTHAEMIA: TWO YEARS TREATAMENT EVALUTATION
- Author
-
GUGLIOTTA L., BULGARELLI S., VIANELLI N., R.U.S.S.O.D., GAMBERI B., CANDONI A., MICHELUTTI T., IMOVILLI A., RUPOLI S., BARULLI S., TASSETTI A., LATAGLIATA R., FRATTARELLI N., SACCHI S., MONTANINI A., MAMMI C., CIANCIA R., ZANCHINI A., ZUMAGLINI F., DE BIASI E., BUCALOSSI A., GENTILI S., MAZZOTTA S., TABILIO A., MARCOMIGNI L., PASSAMONTI F., MALABARBA L., MIGLINO M., VALALDO R., GROSSI A., BALESTRI F., CACCIOLA E., CACCIOLA R., PISAPIA G., POGLIANI E., BONIFAZI F., FANIN R., LEONI P., MANDELLI F., ROTOLI B., ZACCARIA A., LAURIA F., MARTELLI M., LAZZARINO M., GOBBI M., BOSI A., GIUSTOLISI R., MAZZA P., BONVINI L., PISARRA P., FINCATO G., BACCARANI M., MARTINELLI, VINCENZO, Gugliotta, L., Bulgarelli, S., Vianelli, N., R. U. S. S. O., D., Gamberi, B., Candoni, A., Michelutti, T., Imovilli, A., Rupoli, S., Barulli, S., Tassetti, A., Latagliata, R., Frattarelli, N., Sacchi, S., Montanini, A., Mammi, C., Martinelli, Vincenzo, Ciancia, R., Zanchini, A., Zumaglini, F., DE BIASI, E., Bucalossi, A., Gentili, S., Mazzotta, S., Tabilio, A., Marcomigni, L., Passamonti, F., Malabarba, L., Miglino, M., Valaldo, R., Grossi, A., Balestri, F., Cacciola, E., Cacciola, R., Pisapia, G., Pogliani, E., Bonifazi, F., Fanin, R., Leoni, P., Mandelli, F., Rotoli, B., Zaccaria, A., Lauria, F., Martelli, M., Lazzarino, M., Gobbi, M., Bosi, A., Giustolisi, R., Mazza, P., Bonvini, L., Pisarra, P., Fincato, G., and Baccarani, M.
- Abstract
Comunicazione orale Haemathologica, (abstract) vol 88 (suppl) n.ro 15
- Published
- 2003
4. Double autograft approach in heavily pretreated Hodgkin's lymphoma patients
- Author
-
Cavalieri, E., Capria, S., Frattarelli, N., Matturro, A., De Angelis, F., Annechini, G., Ribersani, M., Santini, L., Simone, F., Gozzer, M., Foa, Roberto, Pulsoni, Alessandro, and Meloni, Giovanna
- Published
- 2008
5. Is bone marrow trephine biopsy always mandatory in staging Hodgkin's disease?
- Author
-
Cavalieri, E., Anselmo, A. P., Gianfelici, V., Frattarelli, N., Edoardo Pescarmona, Foà, R., and Pulsoni, A.
- Subjects
Adult ,Male ,Biopsy ,Humans ,Bone Marrow Cells ,Female ,Middle Aged ,Unnecessary Procedures ,Hodgkin Disease ,Aged ,Neoplasm Staging - Abstract
We reviewed data from 690 adult patients with Hodgkin's disease (HD) to determine whether bone marrow trephine biopsy (BMTB) is mandatory for all patients. The data suggest that it is not necessary in clinical stage I-IIA. However, bilateral BMTB is recommended in the presence of B symptoms also in patients with localized stage disease.
- Published
- 2005
6. PEG-Intron in essential thrombocythaemia: two years treatment evaluation
- Author
-
Gugliotta, L, Bulgarelli, S, Vianelli, N, Russo, D, Gamberi, B, Candoni, A, Michelutti, T, Imovilli, A, Rupoli, S, Barulli, S, Tassetti, A, Latagliata, R, Frattarelli, N, Sacchi, S, Montani, Ni, A, Mammi, C, Martinelli, V, Ciancia, R, Zanchini, A, Zumaglini, F, DE BIASI, E, Bucalos, Si, A, Gentili, S, Mazzotta, S, Tabilio, A, Marcomigni, L, Passamonti, F, Malabarba, L, Migli, No, M, Varaldo, R, Grossi, A, Balestri, F, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Pogliani, E, Bonifazi, F, Fanin, R, Leoni, P, Mandelli, F, Rotoli, B, Zaccaria, A, Lauria, F, Martelli, M, Lazzarino, M, Gobbi, M, Bosi, A, Giustolisi, R, Mazza, P, Bovini, L, Pisarra, P, Fincato, G, and Baccarani, M.
- Published
- 2003
7. Peg Interferon a- 2b (Peg Intron) in essential Thrombocythemia
- Author
-
Gugliotta, L, Bulgarelli, S, Vinelli, N, Russo, D, Gamberi, B, Candoni, A, Ruoli, S, Barulli, S, Latagliata, R, Frattarelli, N, Sacchi, S, Serbano, S, Martinelli, V, Ciancia, R, Molinari, A. L, DE BIASI, E, Bucalossi, A, Tabilio, A, Marcomigni, L, Passamonti, F, Miglino, M, Varaldo, R, Grossi, A, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Gentili, S, Pogliani, E, Fincato, G, Baccarani, M., L., Gugliotta, S., Bulgarelli, N., Vianelli, D., Russo, B., Gamberi, A., Candoni, S., Rupoli, S., Barulli, R., Latagliata, N., Frattarelli, S., Sacchi, S., Nerbano, Martinelli, Vincenzo, R., Ciancia, A. L., Molinari, E., DE BIASI, A., Bucalossi, A., Tabilio, L., Marcamigni, F., Passamonti, M., Miglino, R., Varaldo, A., Grossi, E., Cacciola, R., Cacciola, G., Pisapia, S., Gentili, E., Pogliani, G., Fincato, and M., Baccarani
- Abstract
BLOOD, VOL 100 N.RO 11
- Published
- 2002
8. Use of PCR for BCL2/IgH + cells in stage I/II follicular lymphoma to identify positive cells in bone marrow and peripheral blood that can be cleared by lymph-node irradiation
- Author
-
Pulsoni, A., primary, Starza, I. Della, additional, Frattarelli, N., additional, Carlotti, E., additional, Cavalieri, E., additional, Matturro, A., additional, De Angelis, F., additional, Armiento, D., additional, Rambaldi, A., additional, and Foa, R., additional
- Published
- 2008
- Full Text
- View/download PDF
9. Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia
- Author
-
Gugliotta, L., Bulgarelli, S., Vianelli, N., Russo, D., Gamberi, B., Candoni, A., Rupoli, S., Barulli, S., Latagliata, R., Frattarelli, N., Sacchi, S., Nerbano, S., Martinelli, V., Ciancia, R., Molinari, Al, Biasi, E., Bucalossi, A., Tabilio, A., Marcomigni, L., Passamonti, F., Miglino, M., Riccardo Varaldo, Grossi, A., Cacciola, E., Cacciola, R., Pisapia, G., Gentili, S., Pogliani, E., Fincato, G., and Baccarani, M.
- Subjects
Thrombocythemia Interferon Peg Intron [Keywords]
10. Whole-body positron emission tomography using fluorodeoxyglucose (FDG-PET) in the evaluation of residual mass in Hodgkin's disease: A monocentric experience
- Author
-
Cavalieri, E., Gianfelici, V., Cucchi, F., Anselmo, A., Frattarelli, N., mattia falchetto osti, Grapulin, L., Quaresima, M., and Pulsoni, A.
11. Hairy cell leukemia: Prognostic factors and treatment,La tricoleucemia: Prognosi e terapia
- Author
-
Micol Quaresima, Iacobelli, S., Tempera, S., Frattarelli, N., Bizzoni, L., Anaclerico, B., Matturro, A., Cucchi, F., Tafuri, A., and Pulsoni, A.
12. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
- Author
-
Samantha Ferrari, L. Rigacci, Monia Capponi, Alessandro Pulsoni, Giuseppe Visani, Luca De Carolis, Pier Luigi Zinzani, Robin Foà, Paolo Falcucci, Enrico Tiacci, G. Gaidano, Eugenio Lucia, Agostino Antolino, Francesco Zaja, A. Ambrosetti, Stefano Ascani, Roberta Della Seta, Edoardo Simonetti, Natalia Frattarelli, Vincenzo Perriello, Brunangelo Falini, Tiacci E., De Carolis L., Simonetti E., Capponi M., Ambrosetti A., Lucia E., Antolino A., Pulsoni A., Ferrari S., Zinzani P.L., Ascani S., Perriello V.M., Rigacci L., Gaidano G., Seta R.D., Frattarelli N., Falcucci P., Foa R., Visani G., Zaja F., Falini B., Tiacci, E., De Carolis, L., Simonetti, E., Capponi, M., Ambrosetti, A., Lucia, E., Antolino, A., Pulsoni, A., Ferrari, S., Zinzani, P. L., Ascani, S., Perriello, V. M., Rigacci, L., Gaidano, G., Seta, R. D., Frattarelli, N., Falcucci, P., Foa, R., Visani, G., Zaja, F., and Falini, B.
- Subjects
Male ,Neoplasm, Residual ,Hairy Cell ,Drug Resistance ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Bone Marrow ,Recurrence ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Neoplasm ,030212 general & internal medicine ,Vemurafenib ,CD20 ,Aged, 80 and over ,Leukemia, Hairy Cell ,Leukemia ,biology ,Remission Induction ,General Medicine ,Middle Aged ,Progression-Free Survival ,Residual ,Rituximab ,Female ,Human ,medicine.drug ,Adult ,Neutropenia ,03 medical and health sciences ,medicine ,Humans ,Hairy cell leukemia ,Progression-free survival ,Aged ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Cancer ,medicine.disease ,Thrombocytopenia ,Drug Resistance, Neoplasm ,Cancer research ,biology.protein ,business - Abstract
Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase-activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91% of the patients; 35% of the patients had a complete response. However, the median relapse-free survival was only 9 months after treatment was stopped.In a phase 2, single-center, academic trial involving patients with refractory or relapsed HCL, we assessed the safety and efficacy of vemurafenib (960 mg, administered twice daily for 8 weeks) plus concurrent and sequential rituximab (375 mg per square meter of body-surface area, administered for 8 doses over a period of 18 weeks). The primary end point was a complete response at the end of planned treatment.Among the 30 enrolled patients with HCL, the median number of previous therapies was 3. A complete response was observed in 26 patients (87%) in the intention-to-treat population. All the patients who had HCL that had been refractory to chemotherapy (10 patients) or rituximab (5) and all those who had previously been treated with BRAF inhibitors (7) had a complete response. Thrombocytopenia resolved after a median of 2 weeks, and neutropenia after a median of 4 weeks. Of the 26 patients with a complete response, 17 (65%) were cleared of minimal residual disease (MRD). Progression-free survival among all 30 patients was 78% at a median follow-up of 37 months; relapse-free survival among the 26 patients with a response was 85% at a median follow-up of 34 months. In post hoc analyses, MRD negativity and no previous BRAF inhibitor treatment correlated with longer relapse-free survival. Toxic effects, mostly of grade 1 or 2, were those that had previously been noted for these agents.In this small study, a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with refractory or relapsed HCL. (Funded by the European Research Council and others; HCL-PG03 EudraCT number, 2014-003046-27.).
- Published
- 2021
13. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
- Author
-
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, and Falini B
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow pathology, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm, Residual, Neutropenia chemically induced, Progression-Free Survival, Recurrence, Remission Induction, Rituximab adverse effects, Thrombocytopenia chemically induced, Vemurafenib adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Hairy Cell drug therapy, Rituximab administration & dosage, Vemurafenib administration & dosage
- Abstract
Background: Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase-activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91% of the patients; 35% of the patients had a complete response. However, the median relapse-free survival was only 9 months after treatment was stopped., Methods: In a phase 2, single-center, academic trial involving patients with refractory or relapsed HCL, we assessed the safety and efficacy of vemurafenib (960 mg, administered twice daily for 8 weeks) plus concurrent and sequential rituximab (375 mg per square meter of body-surface area, administered for 8 doses over a period of 18 weeks). The primary end point was a complete response at the end of planned treatment., Results: Among the 30 enrolled patients with HCL, the median number of previous therapies was 3. A complete response was observed in 26 patients (87%) in the intention-to-treat population. All the patients who had HCL that had been refractory to chemotherapy (10 patients) or rituximab (5) and all those who had previously been treated with BRAF inhibitors (7) had a complete response. Thrombocytopenia resolved after a median of 2 weeks, and neutropenia after a median of 4 weeks. Of the 26 patients with a complete response, 17 (65%) were cleared of minimal residual disease (MRD). Progression-free survival among all 30 patients was 78% at a median follow-up of 37 months; relapse-free survival among the 26 patients with a response was 85% at a median follow-up of 34 months. In post hoc analyses, MRD negativity and no previous BRAF inhibitor treatment correlated with longer relapse-free survival. Toxic effects, mostly of grade 1 or 2, were those that had previously been noted for these agents., Conclusions: In this small study, a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with refractory or relapsed HCL. (Funded by the European Research Council and others; HCL-PG03 EudraCT number, 2014-003046-27.)., (Copyright © 2021 Massachusetts Medical Society.)
- Published
- 2021
- Full Text
- View/download PDF
14. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
- Author
-
Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, and Pulsoni A
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aspergillosis chemically induced, Bleomycin administration & dosage, Bleomycin adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Doxorubicin administration & dosage, Doxorubicin adverse effects, Drug Resistance, Neoplasm, Etoposide administration & dosage, Etoposide adverse effects, Female, Hodgkin Disease surgery, Humans, Male, Middle Aged, Pericarditis chemically induced, Peripheral Blood Stem Cell Transplantation, Pneumonia chemically induced, Prednisone administration & dosage, Prednisone adverse effects, Procarbazine administration & dosage, Procarbazine adverse effects, Recurrence, Retrospective Studies, Shock, Septic chemically induced, Survival Analysis, Treatment Outcome, Vincristine administration & dosage, Vincristine adverse effects, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy
- Abstract
The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory to first-line therapy achieve a durable response after peripheral blood stem cell transplantation (PBSCT). Patients relapsing after a PBSCT (performed as second line therapy) have a very poor prognosis. We evaluated the efficacy of BEACOPP in two settings: patients refractory or in relapse after first-line therapy (Group A) and patients relapsing after a PBSCT (Group B). Twenty-three patients with HL, admitted between February 2003 and April 2007, were retrospectively studied: 10 patients in Group A and 13 in Group B. Group A: Nine complete remissions (CR) and one partial remission (PR) were achieved following BEACOPP treatment. After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease. Group B: Eight of the 13 patients (62%) obtained a CR, one patient a PR, two were refractory and two have died of toxicity. To date, eight patients (62%) are alive, four (31%) still in CR. All patients experienced hematologic toxicity (WHO 3-4) with two deaths due to septic shock. These results show that BEACOPP is an effective regimen for both refractory/relapsed patients with HL after first-line treatment (Group A) and for patients relapsing after a PBSCT (Group B) with a 3-year probability of overall survival, progression-free survival, and cumulative incidence of relapse of 90, 50, and 33.3% in Group A, and 61, 31, and 37.5% in Group B, respectively.
- Published
- 2009
- Full Text
- View/download PDF
15. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy.
- Author
-
Pulsoni A, Starza ID, Frattarelli N, Ghia E, Carlotti E, Cavalieri E, Matturro A, Tempera S, Rambaldi A, and Foà R
- Subjects
- Adult, Aged, Bone Marrow Cells pathology, Female, Humans, Lymphoma, Follicular genetics, Lymphoma, Follicular physiopathology, Male, Middle Aged, Neoplasm Staging, Polymerase Chain Reaction methods, Bone Marrow pathology, Genes, bcl-2 genetics, Lymphoma, Follicular radiotherapy
- Abstract
Stage I/IIA follicular lymphoma (FL) is considered a localised disease that can be adequately treated with radiotherapy alone. Bone marrow (BM) and peripheral blood (PB) involvement in FL was investigated by polymerase chain reaction (PCR) in a series of 24 consecutive patients with histologically revised diagnosis and treated with involved field radiotherapy. Despite the limited stage, Bcl-2/IgH+ cells were found at diagnosis in PB and/or BM of 16 patients (66.6%). After treatment, in 9/15 Bcl-2/IgH positive evaluable patients, a disappearance of Bcl-2/IgH+ cells was observed, which persisted after a median follow-up of 43.5 months (range 11-70) in all but one patient. Quantitative PCR demonstrated the feasibility of clearing PB and BM Bcl-2+ cells after local irradiation of the primary site of the disease only when the basal number of lymphoma cells was <1:100 000. Patients with Bcl-2/IgH+ cells at diagnosis or after treatment had a higher likelihood of relapse. Thus, despite a negative BM biopsy, the majority of localised FL Bcl-2/IgH+ cells were found in the PB and BM. Lymphoma cells can reversibly spread from the affected lymph node to PB and BM and, in a proportion of cases, durably disappear after irradiation. The possibility of a persistent lymphoma cell clearance is proportional to the amount of cells detected at presentation by quantitative PCR.
- Published
- 2007
- Full Text
- View/download PDF
16. [Hairy cell leukemia: prognosis and treatment].
- Author
-
Quaresima M, Iacobelli S, Tempera S, Frattarelli N, Bizzoni L, Anaclerico B, Matturro A, Cucchi F, Tafuri A, and Pulsoni A
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Marrow pathology, Female, Follow-Up Studies, Hemoglobins metabolism, Humans, Interferon-alpha administration & dosage, Leukemia, Hairy Cell blood, Leukemia, Hairy Cell mortality, Leukemia, Hairy Cell pathology, Leukocyte Count, Male, Middle Aged, Pentostatin administration & dosage, Platelet Count, Prognosis, Retrospective Studies, Splenectomy, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Hairy Cell drug therapy
- Abstract
Aims: To analyze clinical and laboratory features at presentation in correlation to treatment response and overall survival; evaluation of different treatment approaches., Methods: The data of 151 consecutive HCL patients observed between 1982 and 2005 were retrospectively analyzed., Results: The following data at presentation were analyzed and compared to response, DFS, PFS and OS: Hb < 10 g/dl (observed in 27% of patients); Plt < 100,000/microl (72%); WBC > 10,000/microl (15%); Splenomegaly (75%); Bone marrow involvement > 70% (27%). At univariate analysis only WBC > 10,000/microl resulted significantly correlated to reduced PFS. 88 Pts received as first line treatment alpha2-interferon (IFN) alone, 49 purine analogues (PA) alone or in combination with IFN, 5 were treated with splenectomy. Among IFN treated patients CR, PR and SD were obtained in 21.6%, 73.8%, 4.5% respectively of the patients; while among PA treated patients in: 26.5%, 71.4%, 2.0% respectively. DFS was significantly prolonged in patients treated with PA with respect to IFN. No significant difference in OS was observed. Median PFS was 27.6 months, median OS is projected at 238 months after a median follow up of 131 months., Conclusions: Among the routine clinical and hematochemical baseline features only the presence of WBC > 10,000/microl was correlated to a lower PFS. First line treatment with purine analogues is correlated to prolonged PFS and DFS with respect to IFN; nevertheless no difference is observed in OS.
- Published
- 2006
17. Conservative treatment for patients over 80 years with acute myelogenous leukemia.
- Author
-
Latagliata R, Alimena G, Carmosino I, Breccia M, Borza PA, Bongarzoni V, Copia C, Spadea A, Pinazzi B, Frattarelli N, Ferrara F, Petti MC, and Mandelli F
- Subjects
- Aged, Antineoplastic Agents adverse effects, Drug Administration Schedule, Female, Humans, Male, Palliative Care, Retrospective Studies, Aged, 80 and over, Antineoplastic Agents therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
In order to evaluate the best treatment of very elderly patients with AML, we have retrospectively analyzed 60 cases of patients aged more than 80 years, with a diagnosis of AML and observed from January 1988 to December 1998. Six of these patients were subsequently referred to other centers; of the remaining 54 patients, 20 (37%) received only supportive care, whereas 34 (63%) required palliative chemotherapy to control leukocytosis, after a median time from diagnosis of 9 days (range 0-253). Median overall survival was 13 weeks (range 1-105): 21 (39%) and 6 (11%) patients survived more than 6 and 12 months, respectively. Twenty-eight patients (51.8%) died from progressive disease, 19 (35.1%) died from AML-related or unrelated causes in the phase of stable disease, while in 7 patients the cause of death was unknown. In univariate analysis, PS > 2 and WBC > 50 x 10(9)/L had an adverse prognostic significance on survival. Our results, as compared with those reported in the literature for patients over 80 years treated with intensive chemotherapy, support the idea that intensive chemotherapy is usually not indicated in very elderly patients with AML, and that conservative treatment and the primary strategy of "watch-and-wait" presently seems to be the best choice., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.